Management of Daytime Agitation in Alzheimer's Disease

Introduction to Quetiapine Management

The American Academy of Family Physicians recommends quetiapine as an atypical antipsychotic that can effectively manage agitation and aggression in Alzheimer's disease patients, with initial recommended dosing of 12.5 mg twice daily and maximum dosing of 200 mg twice daily 1
Adding a morning dose of quetiapine 25 mg is appropriate for patients with Alzheimer's disease who have persistent daytime agitation despite the 50 mg bedtime dose, following the recommended approach for managing persistent symptoms 1, 2

Total daily dose after adding the morning 25 mg will be 75 mg, which is well within the safe range for elderly patients 1

Monitor for common side effects including sedation and orthostatic hypotension, particularly with the morning dose, as well as extrapyramidal symptoms, though these are less common with quetiapine than with typical antipsychotics 1
Assess response to the added morning dose after 2-4 weeks to determine efficacy 3, 4

Atypical antipsychotics like quetiapine carry an FDA black box warning regarding increased mortality risk in elderly patients with dementia-related psychosis 1
Consider non-pharmacological approaches alongside medication management, including structured activities, reassurance, socialization, and caregiver education, as well as environmental safety measures and supervision 5

Consider mood stabilizers like trazodone or divalproex sodium if quetiapine is ineffective 2
For mild to moderate agitation, buspirone may be considered, with an initial dose of 5 mg twice daily 6
Avoid benzodiazepines when possible due to risk of tolerance, addiction, cognitive impairment, and paradoxical agitation in about 10% of elderly patients 2